Clinical Data on Lenocta(TM), a Protein Tyrosine Phosphatase Inhibitor in Development at VioQuest Pharmaceuticals, Inc., Accepted for Oral Presentation at American Society of Clinical Oncology

BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) today announced that the American Society of Clinical Oncology (ASCO) has accepted for oral presentation the Company's abstract for Lenocta™ (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases. The abstract titled “Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alpha for patients with solid tumors”, is scheduled to be presented at the 44th ASCO Annual Meeting, May 30 - June 3, 2008 in Chicago, Illinois.